pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

5,573 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1894Endpoints1467Fierce Biotech779BioSpace768BioPharma Dive555raps257onclive165fda recalls
therapy area
allOncology13097Rare Disease3403Immunology3069Cardiology2870Hematology2337Pulmonology2300
  • Capricor Therapeutics receives second FDA rejection for Duchenne cell therapy deramiocel
    The U.S. Food and Drug Administration issued a second complete response letter rejecting Capricor Therapeutics' cell therapy deramiocel for Duchenne muscular dystrophy. The agency said the data did…
    BioSpace · 2h agoCRLNegative↗ source
  • FDA rejects Capricor's Duchenne cell therapy again, citing major trial flaws
    Capricor Therapeutics' deramiocel cell therapy for Duchenne muscular dystrophy was denied by the FDA for a second time. The agency highlighted significant issues with the trial design and data, le…
    Endpoints · 15h agoRegulatoryNegative↗ source
← prev
page 1 of 223
next →
126
fda medwatch117
globenewswire health73
fda press62
Vaccines1892
Psychiatry & CNS1247
Ophthalmology1150
Endocrinology & Metabolism809
Pain801
Nephrology789
  • Kennedy and MAHA urged to champion MMR vaccine to curb U.S. measles surge
    After the United States lost its measles elimination status, health secretary Robert F. Kennedy Jr. used his X account to pledge action, stating the MMR vaccine remains the most effective tool to s…
    STAT · 7h agoPositive↗ source
  • Debate Over Whether Medical School Should Begin After USMLE Step 1 Exam
    STAT published an opinion essay proposing that medical school start after students take the Step 1 exam. The piece prompted letters to the editor, with readers offering personal reflections on the…
    STAT · 4h agoNeutral↗ source
  • Biopharma newsletter released despite tech outages, highlights Washington political news
    The latest edition of a biopharma newsletter was published even though the week was marked by several technology outages. The issue notes that the most significant story came from Washington, wher…
    Endpoints · 5h agoNeutral↗ source
  • RevMed's Rasonque shows strong first-line response and survival benefit in early pancreatic cancer data
    RevMed reported early-stage results from its open‑label Phase 1/2 RMC‑GI‑102 trial, presented at the EORTC‑N conference, evaluating Rasonque combined with chemotherapy in patients with first‑line m…
    BioSpace · 1d agoPositive readoutPositive↗ source
  • Sanofi weighs $40 billion Insmed acquisition, seen as strategic fit in respiratory market
    Analysts are reporting that Sanofi is considering buying Insmed, a biotech focused on respiratory therapies. The potential transaction could be valued at up to $40 billion, making it one of the lar…
    BioSpace · 1d agoDealPositive↗ source
  • Merck’s TROP2 ADC extends survival in pivotal gastroesophageal cancer trial
    Merck & Co.’s sacituzumab tirumotecan has improved overall survival in a phase 3 cancer trial, delivering a second pivotal global victory for the TROP2-directed antibody-drug conjugate.
    Fierce Biotech · 1d agoPositive readoutPositive↗ source
  • FDA rejects Capricor’s Duchenne cell therapy after trials show no benefit
    The Food and Drug Administration announced that it is rejecting deramiocel, a cell therapy for Duchenne muscular dystrophy developed by Capricor Therapeutics. The treatment was aimed at teenage an…
    STAT · 17h agoRegulatoryNegative↗ source
  • Revolution Medicines reports strong data for KRAS-targeted pancreatic cancer drug amid rising competition
    Revolution Medicines presented encouraging results for its KRAS‑targeted therapy aimed at pancreatic cancer at a recent industry meeting. The company highlighted the potency of the drug in preclini…
    Endpoints · 1d agoPositive readoutNeutral↗ source
  • Merck's sac-TMT antibody-drug conjugate achieves positive Phase 3 results in gastric cancer
    Merck announced that its experimental antibody-drug conjugate sacituzumab-TMT (sac-TMT) met primary endpoints in a pivotal Phase 3 trial in patients with gastric cancer. The trial outcome represen…
    Endpoints · 1d agoPositive readoutPositive↗ source
  • Merck-Kelun ADC sac-TMT shows overall survival benefit in Phase 3 stomach cancer trial
    Merck, licensing the TROP2-targeting antibody drug conjugate sac-TMT from Kelun-Biotech, reported that the therapy improved overall survival in patients with advanced gastroesophageal adenocarcinom…
    BioSpace · 1d agoPositive readoutPositive↗ source
  • Greenwich Rx voluntarily recalls compounded sterile products over sterility concerns
    Greenwich Rx, a 503A compounding pharmacy based in Tomball, Texas, announced a voluntary nationwide recall of certain compounded sterile product lots that are still within their beyond-use dates.…
    fda recalls · 17h agoCRLNegative↗ source
  • Lawmakers split on US restrictions for China biotech investments
    Ahead of the upcoming Democrat-controlled Congress, lawmakers from both parties are articulating new positions on whether the United States should limit investments in China's rapidly growing biote…
    Endpoints · 21h agoRegulatoryNeutral↗ source
  • FDA delays decision on Savara's rare lung disease therapy, pushing back deadline
    The FDA announced it will not meet the Nov. 22 PDUFA date for Savara's biologics license application for its inhaled therapy molgramostim (Molbreevi) targeting autoimmune pulmonary alveolar protein…
    BioSpace · 1d agoRegulatoryNegative↗ source
  • Sanofi considers Insmed acquisition as FDA criticizes J&J bladder cancer drug claims; Japan eyes higher drug prices
    Sanofi is reportedly evaluating a possible takeover of Insmed, signaling continued consolidation activity in the biotech sector. The U.S. Food and Drug Administration has issued a warning to Johns…
    STAT · 1d agoDealNeutral↗ source
  • Celldex drops eczema antibody barzolvolimab after Phase 2 failure
    Celldex Therapeutics said it is ending development of its monoclonal antibody barzolvolimab as a treatment for eczema. The Phase 2 study did not show a statistically significant reduction in itchi…
    Endpoints · 1d agoNegative readoutNegative↗ source
  • FDA leadership search continues as lung cancer drug faces rejection and China’s top drugmakers are ranked
    The Readout LOUD podcast this week highlighted three main topics: the FDA’s ongoing search for a new commissioner, a setback for a closely watched lung cancer therapy, and a ranking of China’s bigg…
    STAT · 1d agoRegulatoryNeutral↗ source
  • FDA delays decision on Belite Bio's Stargardt disease drug to May 12
    The FDA announced it will extend its review of Belite Bio's new drug application for tinlarebant, an oral small-molecule intended to treat Stargardt disease type 1, moving the PDUFA action date fro…
    Fierce Biotech · 1d agoRegulatoryNeutral↗ source
  • Heraeus Medevio issues recall of vascular guidewires over coating safety risk
    The FDA's Center for Devices and Radiological Health has posted an Early Alert warning about a potentially high‑risk issue with certain vascular guidewires. The alert notes that the coating on the…
    fda medwatch · 1d agoRegulatoryNegative↗ source
  • Bausch + Lomb and Celldex report phase 2 trial failures in atopic dermatitis
    Both Bausch + Lomb and Celldex Therapeutics announced that their recent phase 2 studies did not achieve primary efficacy goals. Celldex’s anti‑KIT antibody barzolvolimab showed no statistically si…
    Fierce Biotech · 1d agoNegative readoutNegative↗ source
  • ICH Q1 Stability Testing Guideline Revision Expected Within Weeks
    The International Council for Harmonization announced that the revised ICH Q1 stability testing guideline has been adopted and will be published soon. The new version will be issued as a Step 4 gu…
    raps · 1d agoRegulatoryNeutral↗ source
  • Commenters urge FDA to allow flexible trial designs for rare diseases, questioning RCT emphasis
    Stakeholders who submitted comments to the FDA’s public docket on statistical methods for rare disease studies emphasized the need for greater flexibility in how trials are designed and what types…
    raps · 1d agoRegulatoryNeutral↗ source
  • Big pharma say they will stop opening new trial sites in Xinjiang and Chinese military hospitals
    Several of the world’s largest pharmaceutical companies told a U.S. House Select Committee on China that they will not start new clinical trial sites in the Xinjiang region of China or at hospitals…
    STAT · 1d agoRegulatoryNegative↗ source
  • Novo announces layoff of 215 New Jersey staff as Bausch + Lomb trial misses endpoint
    Novo Pharma said it will cut 215 positions at its Plainsboro, New Jersey facility, with the reductions slated to begin in February 2027. The move adds to a series of recent workforce reductions ac…
    Endpoints · 1d agoLayoffsNegative↗ source